Utama › Melanoma › Michigan › Ann Arbor
Kajian klinikal Melanoma di Ann Arbor, MI
12 kajian untuk Melanoma sedang mencari peserta di lokasi dalam dan sekitar Ann Arbor (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi jauh
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi jauh
- dan 4 lagi
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Mengambil pesertaFasa 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi jauh
- dan 5 lagi
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Mengambil pesertaFasa 3
- University of Michigan, Ann Arbor
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Mengambil pesertaFasa 2
- Local Institution - 0119, Ann Arbor
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Mengambil pesertaFasa 2
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- University of Michigan - Brighton Center for Specialty Care, Brighton · 18 mi jauh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Mengambil pesertaFasa 1/2
- C S Mott Children's Hospital, Ann Arbor
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- C S Mott Children's Hospital, Ann Arbor
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Mengambil pesertaFasa 3
- W Kellogg Eye Center, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Ann Arbor
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Mengambil peserta
- University of Michigan, Ann Arbor
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Mengambil peserta
- University of Michigan Medical Center, Ann Arbor
- University of Michigan - Brighton Center for Specialty Care, Brighton · 18 mi jauh
Kajian Melanoma di bandar lain
- Houston, TX59 kajian
- New York City, NY38 kajian
- Los Angeles, CA34 kajian
- Nashville, TN33 kajian
- Pittsburgh, PA31 kajian
- Boston, MA26 kajian
- Philadelphia, PA23 kajian
- San Francisco, CA22 kajian
- Durham, NC21 kajian
- Atlanta, GA21 kajian
- St. Louis, MO21 kajian
- Salt Lake City, UT21 kajian
Kajian lain di Ann Arbor
- Kanser Prostat27 kajian
- Kanser Payudara26 kajian
- Kanser Paru-paru Bukan Sel Kecil26 kajian
- Kanser (semua jenis)25 kajian
- Kanser Kolorektal23 kajian
- Kanser Paru-paru23 kajian
- Kegagalan Jantung22 kajian
- Leukemia Mieloid Akut17 kajian
- Penyakit Kardiovaskular16 kajian
- Kanser Pankreas14 kajian
- Kanser Ginjal (Karsinoma Sel Renal)12 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher12 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.